Dr Matthew Segall

Matthew Segall

CEO

Optibrium Limited

Research

Computational Chemistry, Artificial Intelligence, Drug Discovery

Interests

The application of imputation methods to data from in vitro models to understand mechanism of action and predict downstream, in vivo or clinical outcomes.